SCHEMBL207164

SCHEMBL207164

Clc1cc(Nc2nc(-c3cccnc3)cs2)ccc1N1CCOCC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 4/20 0.68
CYP1A2 P05177 4/20 0.68
CYP1B1 Q16678 4/20 0.68
MEN1 O00255 11/20 0.68
KMT2A Q03164 11/20 0.68
RAB9A P51151 5/20 0.68
MAPT P10636 6/20 0.60
ALDH1A1 P00352 3/20 0.60
NPC1 O15118 4/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
MAPK1 P28482 2/20 0.56
ALOX5 P09917 1/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
PKM P14618 2/20 0.54
LMNA P02545 2/20 0.54
GAA P10253 2/20 0.54
VCP P55072 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204698 0.86 CYP1A1 (0.90) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL12297742 0.82 MEN1 (0.80) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL28716321 0.81 CYP1B1 (1.00) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL29654148 0.81 CYP1B1 (1.00) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL12297978 0.77 ALOX5 (0.78) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL206574 0.76 CYP1A1 (0.74) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL208226 0.76 MEN1 (0.75) MEN1KMT2ARAB9AMAPTALDH1A1
SCHEMBL12298037 0.76 ALOX5 (0.57) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL7540052 0.76 MAPK1 (0.84) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL12298381 0.75 ALOX5 (0.59) CYP1A1CYP1A2CYP1B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 CYP1A1 212/4885CYP1A2 603/4885CYP1B1 235/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 CYP1A1 212/4885CYP1A2 603/4885CYP1B1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.